Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID
Open Access
- 9 May 2025
- journal article
- research article
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-12
Abstract
Background: The symptomatic and immune responses to COVID-19 vaccination of people with Long COVID are poorly characterized. Methods: In this prospective study, we evaluated changes in symptoms and immune responses after COVID-19 vaccination in 16 vaccine-naïve individuals with Long COVID. Surveys were administered before vaccination and at 2, 6, and 12 weeks after receiving the first vaccine dose of the primary series. Simultaneously, SARS-CoV-2-reactive TCR enrichment, SARS-CoV-2-specific antibody responses, antibody responses to other viral and self-antigens, and circulating cytokines were quantified before vaccination and at 6 and 12 weeks after vaccination. Results: At 12 weeks post-vaccination, self-reported improved health is seen in 10 out of 16 participants, 3 have no change, and 3 have worse health although 2 report transient improvement after vaccination. One participant reporting worse health was hospitalized twice with chest pain (after each dose). Symptom outcomes are most associated with plasma biosignatures. Higher baseline sIL-6R is associated with symptom improvement, and stably elevated levels of IFN-β and CNTF are associated with no improvement. Significant elevation in SARS-CoV-2-specific TCRs and spike protein-specific IgG are observed at 6 and 12 weeks after vaccination. No changes in reactivities are observed against herpes viruses and self-antigens. Conclusions: In this study of 16 people with Long COVID, vaccination is associated with increased SARS-CoV-2 spike protein-specific IgG and T cell expansion in most participants. Specific immune features are associated with symptom change after vaccination and most participants experience improved health or no change following vaccination.Keywords
All Related Versions
Funding Information
- Howard Hughes Medical Institute
This publication has 40 references indexed in Scilit:
- Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 InfectionJAMA Internal Medicine, 2024
- The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-Blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVIDThe American Journal of Medicine, 2024
- Serotonin reduction in post-acute sequelae of viral infectionCell, 2023
- Vaccination after developing long COVID: Impact on clinical presentation, viral persistence, and immune responsesInternational Journal of Infectious Diseases, 2023
- The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysiseClinicalMedicine, 2022
- Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic revieweClinicalMedicine, 2022
- Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVIDJournal of Medical Virology, 2022
- Symptoms After COVID-19 Vaccination in Patients with Post-Acute Sequelae of SARS-CoV-2Journal of General Internal Medicine, 2022
- Multiple early factors anticipate post-acute COVID-19 sequelaeCell, 2022
- Characterizing long COVID in an international cohort: 7 months of symptoms and their impacteClinicalMedicine, 2021